Sugi Predict

Sugi Predict / Compounds / SCHEMBL258344

SCHEMBL258344

SCHEMBL258344

O=CCN1CCOCC1.[NaH]

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KDM4E B2RXH2 4/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ TSHR P16473 2/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ GLA P06280 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ KEAP1 Q14145 1/20 0.38
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ ANPEP P15144 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165786 0.97 — —
Hydrochloric Acid SCHEMBL29956587 0.95 USP2 (0.44) USP2SMN1; SMN2KDM4EHSD17B10TSHR
Hydrochloric Acid SCHEMBL1430281 0.93 USP2 (0.43) USP2SMN1; SMN2KDM4EHSD17B10TSHR
SCHEMBL20578747 0.89 USP2 (0.40) USP2SMN1; SMN2KDM4EHSD17B10TSHR
SCHEMBL18232546 0.83 — —
SCHEMBL26272100 0.80 HSD17B10 (0.69) USP2SMN1; SMN2KDM4EHSD17B10TSHR
Trifluoroacetic Acid SCHEMBL2999604 0.80 KCNJ1 (0.45) USP2SMN1; SMN2KDM4EHSD17B10TSHR
SCHEMBL27018306 0.80 HSD17B10 (0.69) USP2SMN1; SMN2KDM4EHSD17B10TSHR
SCHEMBL27303608 0.80 HSD17B10 (0.69) USP2SMN1; SMN2KDM4EHSD17B10TSHR
SCHEMBL3345471 0.78 KDM4E (0.40) USP2SMN1; SMN2KDM4EHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115466231-B Method for preparing 3- [2- (4-morpholinyl) ethoxy ] propionitrile by pipelining 浙江大学 2024-03-08 — — CN claimed
CN-115466231-B Method for preparing 3- [2- (4-morpholinyl) ethoxy ] propionitrile by pipelining 浙江大学 2024-03-08 — — CN disclosed
CN-115557916-B Preparation method of morpholinylethyl dimethylaminopropyl ether 恒光新材料(江苏)股份有限公司 2023-11-14 — — CN disclosed
CN-115557916-A Process for preparation of morpholinylethyldimethylaminopropyl ether 南通恒光大聚氨酯材料有限公司 2023-01-03 — — CN disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 — — US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 — — EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7037915-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 — — US disclosed
US-20060058321-A1 Fused heterolaryl derivatives HAYAKAWA MASAHIKO 2006-03-16 — — US disclosed
US-20050014771-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2005-01-20 — — US disclosed
US-6838457-B2 Fused heteroaryl derivatives YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-04 — — US disclosed
US-6770641-B2 Fused heteroaryl derivatives YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2004-08-03 — — US disclosed
US-20040009978-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2004-01-15 — — US disclosed
US-20030236271-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2003-12-25 — — US disclosed
US-6608056-B1 Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) 2003-08-19 — — US disclosed
US-6608053-B2 Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 — — US disclosed
EP-1277738-A1 CONDENSED HETEROARYL DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 — — EP disclosed
US-20020151544-A1 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236271-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885
US-20040009978-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885
US-20060058321-A1 Fused heterolaryl derivatives PIK3CD, PIK3C2A, PIK3R1 USP2 2036/4885SMN1; SMN2 4775/4885KDM4E 2443/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885
US-20020151544-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885
US-20050014771-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A USP2 2433/4885SMN1; SMN2 4764/4885KDM4E 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.